Clinical Trials Logo

ALK Gene Mutation clinical trials

View clinical trials related to ALK Gene Mutation.

Filter by:

NCT ID: NCT03868423 Withdrawn - Clinical trials for Metastatic Malignant Solid Neoplasm

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Start date: March 20, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03049618 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombinant EphB4-HSA fusion protein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab may work better in treating patients with non-small cell lung or head and neck squamous cell cancer.

NCT ID: NCT03042221 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Start date: May 10, 2016
Phase:
Study type: Observational

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.

NCT ID: NCT01700582 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Start date: April 2012
Phase:
Study type: Observational

The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).